|
|
Vaccine Detail
|
Dendritic Cell-targeting Lentiviral Vector ID-LV305 |
| Vaccine Information |
- Vaccine Name: Dendritic Cell-targeting Lentiviral Vector ID-LV305
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007374
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- NY-ESO-1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. (NCIT_C115976).
|
| Host Response |
|
|
| References |
NCIT_C115976: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115976]
|
|
